KMT2A and leukemia: Furthermore, MYC is a well-known proto-oncogene that is frequently over-expressed in cancer, including in ALL, AML, and MLL-r leukemias (Schreiner et al., 2001; Langenau et al., 2003; Luo et al., 2005; Delgado and León, 2010; Dang, 2012; Li L. et al., 2014; Sanchez-Martin and Ferrando, 2017).